CN112481337B - 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量 - Google Patents

调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量 Download PDF

Info

Publication number
CN112481337B
CN112481337B CN202011124768.1A CN202011124768A CN112481337B CN 112481337 B CN112481337 B CN 112481337B CN 202011124768 A CN202011124768 A CN 202011124768A CN 112481337 B CN112481337 B CN 112481337B
Authority
CN
China
Prior art keywords
ornithine
cells
inhibitor
cell
recombinant protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011124768.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112481337A (zh
Inventor
S·康
C·小黄
H·巴霍尔达里安
P·邦达伦科
Z·张
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52273554&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN112481337(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to CN202011124768.1A priority Critical patent/CN112481337B/zh
Publication of CN112481337A publication Critical patent/CN112481337A/zh
Application granted granted Critical
Publication of CN112481337B publication Critical patent/CN112481337B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/73—Hydrolases (EC 3.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202011124768.1A 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量 Active CN112481337B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011124768.1A CN112481337B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461926481P 2014-01-13 2014-01-13
US61/926481 2014-01-13
CN201480073081.6A CN106029896B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
CN202011124768.1A CN112481337B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
PCT/US2014/069378 WO2015105609A1 (en) 2014-01-13 2014-12-09 Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480073081.6A Division CN106029896B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量

Publications (2)

Publication Number Publication Date
CN112481337A CN112481337A (zh) 2021-03-12
CN112481337B true CN112481337B (zh) 2024-06-25

Family

ID=52273554

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011124768.1A Active CN112481337B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
CN201480073081.6A Active CN106029896B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201480073081.6A Active CN106029896B (zh) 2014-01-13 2014-12-09 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量

Country Status (14)

Country Link
US (2) US10513723B2 (enExample)
EP (1) EP3094735A1 (enExample)
JP (1) JP6732660B2 (enExample)
KR (1) KR102381791B1 (enExample)
CN (2) CN112481337B (enExample)
AU (3) AU2014376225C1 (enExample)
BR (2) BR112016015797B1 (enExample)
CA (1) CA2936104C (enExample)
CL (3) CL2016001786A1 (enExample)
EA (2) EA202191909A1 (enExample)
IL (1) IL246727B (enExample)
MX (2) MX384153B (enExample)
SG (2) SG11201605640UA (enExample)
WO (1) WO2015105609A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN114075269A (zh) * 2017-07-06 2022-02-22 菲仕兰坎皮纳荷兰私人有限公司 用于制备糖蛋白的细胞培养工艺
RU2672318C1 (ru) * 2017-09-19 2018-11-13 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения моноклональных антител терапевтического назначения с помощью непрерывного культивирования клеток сно
CN111527214B (zh) 2017-12-20 2024-08-06 阿雷斯贸易股份有限公司 用聚醚离子载体调整蛋白质甘露糖基化状况的方法
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111671051B (zh) * 2020-07-30 2022-01-11 广州同康生物科技有限公司 一种整粒黄豆中嘌呤的脱除工艺

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
WO1994010308A1 (en) 1992-10-23 1994-05-11 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
WO2001036637A1 (en) 1999-11-17 2001-05-25 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
CA2838695C (en) 2011-07-01 2017-02-14 Amgen Inc. Mammalian cell culture

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans;Andrew M Goetze等;Glycobiology;20110318;第21卷(第7期);949-959 *
Increased productivity of recombinant tissular plasminogen activator (t-PA) by butyrate and shift of temperature: A cell cycle phases analysis;V. Hendrick等;Cytotechnology;第36卷(第1期);71-83 *

Also Published As

Publication number Publication date
SG11201605640UA (en) 2016-08-30
AU2014376225A1 (en) 2016-07-21
AU2020260443A1 (en) 2020-11-26
IL246727A0 (en) 2016-08-31
CL2018002548A1 (es) 2018-10-26
MX384153B (es) 2025-03-14
AU2018226416B2 (en) 2020-08-27
IL246727B (en) 2020-05-31
MX2016009084A (es) 2016-10-13
AU2018226416C1 (en) 2025-11-06
AU2014376225B2 (en) 2018-06-07
US10513723B2 (en) 2019-12-24
AU2018226416A1 (en) 2018-09-27
CA2936104C (en) 2022-04-19
EA202191909A1 (ru) 2022-01-31
EP3094735A1 (en) 2016-11-23
JP6732660B2 (ja) 2020-07-29
CN106029896B (zh) 2020-10-27
CN106029896A (zh) 2016-10-12
US20160333385A1 (en) 2016-11-17
EA201691426A1 (ru) 2016-11-30
SG10201806643WA (en) 2018-09-27
KR102381791B1 (ko) 2022-03-31
US11254963B2 (en) 2022-02-22
CL2022000470A1 (es) 2022-10-21
JP2017501749A (ja) 2017-01-19
MX376230B (es) 2025-03-07
US20200071738A1 (en) 2020-03-05
BR122020004385B1 (pt) 2022-10-04
BR112016015797B1 (pt) 2022-10-11
KR20160104073A (ko) 2016-09-02
AU2014376225C1 (en) 2025-06-05
WO2015105609A1 (en) 2015-07-16
CN112481337A (zh) 2021-03-12
AU2020260443B2 (en) 2022-10-27
EA039141B1 (ru) 2021-12-09
CA2936104A1 (en) 2015-07-16
BR112016015797A2 (enExample) 2017-10-03
CL2016001786A1 (es) 2017-06-02

Similar Documents

Publication Publication Date Title
AU2020260443B2 (en) Regulating Ornithine Metabolism To Manipulate The High Mannose Glycoform Content Of Recombinant Proteins
US9388447B2 (en) Method for culturing mammalian cells to improve recombinant protein production
US11434514B2 (en) Methods for increasing mannose content of recombinant proteins
US9012178B2 (en) Dipeptides to enhance yield and viability from cell cultures
WO2008154014A2 (en) A method for culturing mammalian cells to improve recombinant protein production
EA036178B1 (ru) Процесс контроля уровня содержания гликанов в составе гликопротеинов
TW201441368A (zh) 用於增加重組蛋白質之甘露糖含量之方法
HK1230239B (zh) 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
HK1230239A1 (en) Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
EA047861B1 (ru) Регулирование метаболизма орнитина для управления содержанием высокоманнозных гликоформ рекомбинантных белков

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant